US Pharma MarketingRoche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown
Roche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Roche is paying Nurix Therapeutics $700 million upfront for rights to bexobrutideg, securing a stake in a BTK degrader that is set to go head-to-head against Eli Lilly’s Jaypirca in a phase 3 trial.
Source: FierceBiotech